SC (Adults and Children): Dose is administered 1 wk after IGIV dose. Dose is determined by multiplying previous IGIV dose by 1.37, then divide into weekly doses based on frequency of previous treatment. Recommended dose is 100–200 mg/kg/wk.
Hepatitis A Prophylaxis (IM)
IM (Adults and Children): 0.02 ml/kg (for pre-exposure prophylaxis, higher doses — 0.06 ml/kg q 4–6 mo are used if exposure will last >3 mo) .
Measles Prophylaxis (IM)
IM (Adults and Children): 0.25 ml/kg (0.5 ml/kg if immunosuppressed; not to exceed 15 ml).
Immunoglobulin Deficiency (IM)
IM (Adults and Children): 1.3 ml/kg initially , then 0.66 ml/kg q 3–4 wk .
IM (Adults and Children): 0.6–1.2 ml/kg if varicella zoster immune globulin is unavailable.
IM (Adults and Children): 0.55 ml/kg.
IV (Adults and Children): 200–800 mg (4–8 ml)/kg monthly; if response is inadequate, may be given twice monthly.
IV (Adults and Children): 0.4 g/kg/day for 2–5 days; additional doses of 0.4 g/kg may be given as needed (other regimens are used).
Idiopathic Thrombocytopenic Purpura
IV (Adults and Children): 0.4 g/kg/day for 2–5 days; then 0.4 g/kg single infusion as needed to maintain platelet count of 30,000 cells/mm³ or prevent bleeding; doses up to 0.8–1.0 g/kg may be needed.
IV (Adults and Children): Privigen —1g/kg daily for 2 consecutive days for a total of 2 g/kg.
Prevention of Bacterial Infections in HIV-Infected Patients, or B cell CLL
IV (Adults and Children): 400 mg/kg q 3–4 wk.
IV (Children): 400 mg/kg/day for 4 consecutive days or 1–2 g/kg single dose given with aspirin therapy; must be started within 10 days of onset of symptoms.
History of anaphylactic or severe systemic reaction to administration of human immune globulin; immunoglobulin A (IgA) deficient patients with antibodies against IgA and/or a history of hypersensitivity.
Thrombocytopenia (IM use).
Acid-base disorders (Gamimune N).
Cardiovascular disease or history of thrombotic events ( risk of vascular occlusion).
Renal impairment, age >65 yr, diabetes mellitus volume depletion, sepsis, paraproteinemia or concucurrent use of nephrotoxic agents ( risk of renal failure; uses lower infusion rate).
Products containing sucrose (may have risk of renal failure).
Agammaglobulinemia or hypogammaglobulinemia ( risk of hypotension and anaphylaxis following rapid IV administration).